NASDAQ:PALI Palisade Bio Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.42 +0.03 (+6.44%) (As of 07/5/2022 05:46 PM ET) Add Compare Share Today's Range$0.38▼$0.4450-Day Range$0.40▼$0.8052-Week Range$0.37▼$4.33Volume159,767 shsAverage Volume169,392 shsMarket Capitalization$9.29 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Palisade Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,313.1% Upside$6.00 Price TargetShort InterestHealthy2.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.57) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.00 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Palisade Bio has a forecasted upside of 1,313.1% from its current price of $0.42.Amount of Analyst CoveragePalisade Bio has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.18% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 0.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PALI. Previous Next 2.7 News and Social Media Coverage News SentimentPalisade Bio has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Palisade Bio this week, compared to 1 article on an average week.Search Interest4 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have not sold or bought any company stock.Percentage Held by Insiders25.35% of the stock of Palisade Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.88% of the stock of Palisade Bio is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Palisade Bio are expected to grow in the coming year, from ($0.57) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address About Palisade BioPalisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.Read More PALI Stock News HeadlinesJuly 3, 2022 | americanbankingnews.comPalisade Bio (NASDAQ:PALI) Stock Price Down 2.3%June 29, 2022 | seekingalpha.comPalisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapyJuly 6, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! June 29, 2022 | finance.yahoo.comPalisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel FunctionJune 12, 2022 | americanbankingnews.comPalisade Bio (PALI) versus Its Competitors Head to Head ReviewJune 7, 2022 | finance.yahoo.comPalisade Bio to Present at the 2022 BIO International ConventionMay 13, 2022 | finance.yahoo.comPalisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 10, 2022 | finance.yahoo.comPalisade Bio Announces Inducement Awards Under Inducement Plan for Key New HiresJuly 6, 2022 | Wealthy Millionaire (Ad)1 Stock With Growth PotentialThis could be one of the best stocks to consider during this bear market run.May 6, 2022 | seekingalpha.comPalisade Bio to raise $2M in stock offeringMay 6, 2022 | finance.yahoo.comPalisade Bio Announces $2.0 Million Registered Direct OfferingMay 5, 2022 | seekingalpha.comPalisade Bio gets Chinese regulatory nod to start late-stage study for lead candidateMay 5, 2022 | finance.yahoo.comPalisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal SurgeryMay 2, 2022 | finance.yahoo.comPalisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline AdvancementsApril 29, 2022 | finance.yahoo.comPalisade Bio to Participate in the Virtual Investor Management and KOL Roundtable EventApril 1, 2022 | msn.com4 Penny Stocks Insiders Are Buying: Heritage Global, Palisade Bio And MoreMarch 30, 2022 | finance.yahoo.comCompanies Like Palisade Bio (NASDAQ:PALI) Could Be Quite RiskyMarch 24, 2022 | finance.yahoo.comPalisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-VestMarch 22, 2022 | morningstar.comPalisade Bio Sees Initiating Bowel-Function-Drug Trial After FDA LetterMarch 22, 2022 | morningstar.comPalisade Bio Shares Bounce Off Monday's 52-Week Low After FDA LetterMarch 22, 2022 | msn.comHow Is The Market Feeling About Palisade Bio Inc. - Common Stock?March 22, 2022 | seekingalpha.comPalisade Bio wins FDA nod to run late-stage trial for lead candidateMarch 22, 2022 | finance.yahoo.comPalisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal SurgeryMarch 18, 2022 | seekingalpha.comPalisade Bio files for $100M mixed shelf offeringMarch 18, 2022 | baystreet.caPalisade Drops on ResultsMarch 18, 2022 | finance.yahoo.comPalisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate UpdateMarch 18, 2022 | seekingalpha.comPalisade Bio stock soars 16% as LB1148 reduces extent/severity of post-surgical adhesionsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PALI CUSIPN/A CIK1357459 Webleadingbiosciences.com Phone(858) 704-4900FaxN/AEmployees13Year FoundedN/ACompany Calendar Last Earnings5/13/2022Today7/06/2022Next Earnings (Estimated)8/23/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,313.1%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,145.95% Return on Assets-273.04% Debt Debt-to-Equity RatioN/A Current Ratio4.43 Quick Ratio4.43 Sales & Book Value Annual Sales$10,000.00 Price / Sales929.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book0.82Miscellaneous Outstanding Shares21,880,000Free Float16,333,000Market Cap$9.29 million OptionableNot Optionable Beta1.66 Palisade Bio Frequently Asked Questions Should I buy or sell Palisade Bio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Palisade Bio stock. View analyst ratings for Palisade Bio or view top-rated stocks. What is Palisade Bio's stock price forecast for 2022? 2 brokers have issued 1 year price targets for Palisade Bio's shares. Their PALI stock forecasts range from $5.00 to $7.00. On average, they expect Palisade Bio's share price to reach $6.00 in the next year. This suggests a possible upside of 1,313.1% from the stock's current price. View analysts' price targets for Palisade Bio or view top-rated stocks among Wall Street analysts. How has Palisade Bio's stock price performed in 2022? Palisade Bio's stock was trading at $1.30 at the start of the year. Since then, PALI stock has decreased by 67.3% and is now trading at $0.4246. View the best growth stocks for 2022 here. When is Palisade Bio's next earnings date? Palisade Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 23rd 2022. View our earnings forecast for Palisade Bio. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) announced its quarterly earnings results on Friday, May, 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. View Palisade Bio's earnings history. Who are Palisade Bio's key executives? Palisade Bio's management team includes the following people: Dr. Thomas M. Hallam Ph.D., CEO & Director (Age 47, Pay $644.39k)Mr. J. D. Finley, Chief Financial Officer (Age 64, Pay $519.39k)Dr. Michael John Dawson M.D., Chief Medical Officer (Age 53, Pay $139.55k)Mr. John J. Rodenrys, Co-Founder, EVP & CTO (Age 78)Ms. Sharon McBrayer, Director of OperationsMr. Robert C. McRae, Sr. VP of Operations & Strategic Devel. Who are some of Palisade Bio's key competitors? Some companies that are related to Palisade Bio include Cabaletta Bio (CABA), CASI Pharmaceuticals (CASI), Cidara Therapeutics (CDTX), Protara Therapeutics (TARA), Microbot Medical (MBOT), ERYTECH Pharma (ERYP), X4 Pharmaceuticals (XFOR), Renovacor (RCOR), Elevation Oncology (ELEV), Entera Bio (ENTX), BioCardia (BCDA), Genetic Technologies (GENE), Enzon Pharmaceuticals (ENZN), Idera Pharmaceuticals (IDRA) and Eloxx Pharmaceuticals (ELOX). View all of PALI's competitors. What is Palisade Bio's stock symbol? Palisade Bio trades on the NASDAQ under the ticker symbol "PALI." How do I buy shares of Palisade Bio? Shares of PALI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Palisade Bio's stock price today? One share of PALI stock can currently be purchased for approximately $0.42. How much money does Palisade Bio make? Palisade Bio (NASDAQ:PALI) has a market capitalization of $9.29 million and generates $10,000.00 in revenue each year. The company earns $-26,620,000.00 in net income (profit) each year or ($3.20) on an earnings per share basis. How many employees does Palisade Bio have? Palisade Bio employs 13 workers across the globe. How can I contact Palisade Bio? Palisade Bio's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The official website for Palisade Bio is leadingbiosciences.com. The company can be reached via phone at (858) 704-4900 or via email at investor@senecabio.com. This page (NASDAQ:PALI) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
